

Chain-Shattering Polymeric Therapeutics with On-Demand Drug-Release Capability**


Yanfeng Zhang, Qian Yin, Lichen Yin, Liang Ma, Li Tang, and Jianjun Cheng*

Polymer–drug conjugates are an important polymeric therapeutic (PT) platform^[1] with drug molecules being attached by cleavable linkages to the pendant functional groups of linear, branched, brushed polymers^[2] that are typically synthesized prior to drug conjugation.^[3] The synthesis and conjugation processes developed to date, however, may not provide precise control over the composition and the structure of the conjugates.^[4] When a polymer with a large number of conjugation-amenable, functional side groups is used, for example, the site of conjugation usually cannot be controlled.^[5] As such, batch-to-batch variations of drug loading and release profiles are often observed with polymer–drug conjugates, and these variations may present a key bottleneck to the clinical translation of PTs.^[6]

To address these challenges, we recently reported drug-initiated ring-opening polymerization of lactide and other cyclic esters in the presence of a zinc catalyst, a technique that can provide excellent control over drug loading.^[7] Hydroxy-group-containing drugs are conjugated to polyesters or polycarbonates by an ester linkage, and drug loading can be controlled by tuning the monomer/initiator ratio. Although this technique provides excellent control over drug loading and affords polymer–drug conjugates with controlled structures and compositions, the ability to control drug release from the resulting conjugates is limited: drug molecules are released by means of hydrolysis or enzymatic cleavage of the ester linkage.^[7a] Incorporating a linker that allows trigger-responsive, active release of the terminally conjugated drug remains synthetically challenging.

To develop a new PT with precise control over both drug loading and release, we attempted to incorporate a trigger-responsive domain (TRD) into PTs, aiming to achieve a specific PT structure and to use the TRD to precisely control drug release. One feasible approach would be using multiple drug and TRD molecules as monomers to construct an A/B (TRD/drug) type of condensation polymer. The

resulting PT would have specific repeating units, and therefore specific molecular structure and composition. Drug release would be precisely controlled by the TRD. Application of an external trigger would activate the TRD, which would subsequently induce a chain-shattering type of degradation of the polymer and release of the neighboring drug molecules (Scheme 1). Herein, we report the use of this approach for the design of chain-shattering polymeric therapeutics (CSPTs) and demonstrate the trigger-induced anticancer activity of CSPTs in vitro and in vivo.



Scheme 1. Chain-shattering polymeric therapeutics.


The TRD needs to meet two requirements. First, it should be difunctional and allow for the formation of TRD–drug linkages that are stable under untreated conditions but instantly become unstable when the trigger is applied. Second, the TRD–drug linkage should degrade rapidly on both sides of the TRD to facilitate chain-shattering type of depolymerization and release of drug molecules in their original form. Because (4-aminophenyl)methanol has been used in the design of trigger-responsive carbonate or urethane linkages that can release the conjugated drug molecules by a 1,6-elimination reaction once the protecting group is removed from the aniline moiety (Scheme 2a), we reasoned that 2,6-bis(hydroxymethyl)aniline (**1**, Scheme 2b)^[8] would likely be condensed with a diol drug to form a PT with trigger-responsive carbonate bonds. Once the protecting group was removed from **1**, the PT (two repeating units shown in Scheme 2b) should undergo a 1,4-elimination followed by a 1,8-elimination, leading to chain shattering and the release of the constituent drug molecules.

To determine whether **1** underwent the anticipated elimination reactions, we prepared CPT-**1a**-CPT (Scheme 2c), a conjugate consisting of **1** protected with a UV-sensitive *O*-nitrobenzyloxy-*l*-carbonyl group and attached to two camptothecin (CPT) molecules by carbonate linkages (Scheme 2c, Figure S7 and S8). When CPT-**1a**-CPT was dissolved in acetonitrile/water (9:1, v/v), CPT release was found to be negligible. However, when the conjugate solution was irradiated with UV light (365 nm, 40 mW cm^{−2}) for only 2 min, more than 93 ± 5 % of CPT was released (Figure 1a

[*] Y. Zhang, Q. Yin, L. Yin, L. Ma, L. Tang, Prof. Dr. J. Cheng
Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign
1304 West Green Street, Urbana, IL, 61801 (USA)
E-mail: jianjunc@illinois.edu

[**] This work is supported by Dow Chemical Company. We thank Dr. Liang Hong and Dr. Keith Harris for helpful discussion. Q.Y. was funded at UIUC from NIH National Cancer Institute Alliance for Nanotechnology in Cancer “Midwest Cancer Nanotechnology Training Center” Grant R25 CA154015A.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201300497>.



Scheme 2. a) Degradation of (4-aminophenyl)methanol carbonates and carbamates. b) Degradation of 2,6-bis(hydroxymethyl)aniline (**1**) carbonate units in a CSPT by 1,4- and 1,8-elimination reactions (two repeating units shown in the scheme). c) Synthesis of UV-responsive model drug conjugate CPT-1a-CPT.

and S10), substantiating the expected 1,4- and 1,8-elimination reactions and the feasibility of using **1** and related analogues for the design of CSPTs.

We used 10-hydroxycamptothecin (HCPT) as a model diol drug and synthesized CSPT(**1a**/HCPT) with a molecular weight (M_n) of 4200 g mol⁻¹ and a polydispersity index (PDI) of 1.48 through condensation polymerization (Scheme 3a). To study its UV-triggered degradation, we monitored the change of its M_n value in dimethylformamide (DMF) by means of gel permeation chromatography (GPC). In the absence of UV irradiation, the M_n of CSPT(**1a**/HCPT) remained unchanged in DMF over a long period of time. In contrast, when CSPT(**1a**/HCPT) was irradiated with UV light (365 nm, 40 mW cm⁻²) for 20 min, its M_n changed drastically (from 4200 to 800 g mol⁻¹), and CSPT(**1a**/HCPT) was almost completely degraded (Figure 1b). We then investigated the release of HCPT from CSPT(**1a**/HCPT) in DMF/water (9:1, v/v). Without UV irradiation, the proportion of HCPT released from CSPT(**1a**/HCPT) was negligible (Figure 1c). In comparison, when CSPT(**1a**/HCPT) was irradiated with

UV light for just 2 min, 40% of the HCPT was burst-released in its original form (Figure 1c, S12, and S13). Up to 92% of HCPT was released from CSPT(**1a**/HCPT) when the CSPT(**1a**/HCPT) solution was exposed to UV light for an additional 13 min. The drastic decrease in the M_n of CSPT(**1a**/HCPT) and the rapid release of HCPT suggested that the polymer was degraded by means of a chain-shattering mechanism.

Degradation of the CSPT(**1a**/HCPT) backbone should occur only at **1a** residues from which the *O*-nitrobenzyloxyl-1-carbonyl protecting group has been removed. Once the UV irradiation is stopped, depletion of the protecting group should also stop immediately, resulting in a pause in backbone degradation and HCPT release. The degradation and release should not resume until the trigger (UV light) is reapplied. To verify this expected release behavior, we monitored the release of HCPT from CSPT(**1a**/HCPT) in DMF/water (9:1, v/v) in response to periodic UV irradiation. As expected, when irradiation was turned on for 1 min and then off for 60 min, pulsatile release of HCPT was observed during the 1 min UV-on periods, and minimal drug release was observed during the 60 min UV-off periods (Figure 1d). This pulsatile HCPT release pattern in response to periodic UV irradiation further substantiates the remarkable responsiveness of this class of CSPT.

Because the amine group is another common functional group amenable to conjugation in natural product-based therapeutics, we next determined whether we could apply the CSPT design strategy to amine-containing therapeutics. We selected 9-aminocamptothecin (ACPT) as the monomer for the synthesis of CSPT(**1a**/ACPT), and studied its UV responsiveness (Scheme 3, Figure S5, S15, and S16). ACPT was incorporated to the CSPT(**1a**/ACPT) backbone by one carbonate bond and one urethane bond. The UV responsiveness of and drug release from CSPT(**1a**/ACPT) were similar to those of CSPT(**1a**/HCPT) in DMF/water (9:1, v/v; Figure 1c,d, S14, and S15). Without UV irradiation, ACPT was released from CSPT(**1a**/ACPT) very slowly (Figure 1c). In contrast, when CSPT(**1a**/ACPT) was irradiated with UV light (365 nm, 40 mW cm⁻²) for 2 min, 30% of the ACPT underwent burst release. Up to 88% of ACPT was released when the CSPT(**1a**/ACPT) solution was exposed to UV light for 15 min (Figure 1c). A pulsatile ACPT release pattern was also observed in response to periodic UV irradiation (Figure 1d).




Figure 1. a) Release of CPT from CPT-1a-CPT with or without UV irradiation. b) Gel permeation chromatographic analysis of CSPT(1a/HcPT) 1) before and 2) after UV irradiation (365 nm, 40 mW/cm², 20 min). c) Release of HcPT and ACPT from CSPT(1a/HcPT) and CSPT(1a/ACPT), respectively, with continuous UV irradiation (+UV) for 15 min or without UV irradiation (-UV). d) Pulsatile release of HcPT and ACPT from CSPT(1a/HcPT) and CSPT(1a/ACPT), respectively, in response to periodic UV irradiation for 1 min every 60 min.

We next determined whether other triggers could be used to control the degradation of CSPTs and the release of the constituent drug molecules. 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl-(2,6-bis(hydroxymethyl)phenyl)carbamate (**1b**, Scheme 3), an analogue of **1** with a redox-sensitive protecting group, was synthesized and co-condensed with ACPT (Figure S6). CSPT(**1b**/ACPT) showed the expected H₂O₂-triggered degradation and rapid ACPT release in DMF/water (9:1, v/v; Scheme S9, Figure S17 and S18).

We further investigated whether CSPTs could be used for formulation of nanoparticle (NP)-based delivery systems with on-demand release profiles. By co-precipitating CSPTs with poly(ethylene glycol)-*block*-poly(L-lactide) (PEG₁₁₃-*b*-PLLA₁₈ or PEL) in water (Figure 2a), we obtained the CSPTs/PEL NPs with diameter below 150 nm, very high drug loading (over 48 wt%) and very high loading efficiency (over 92%) (Table S1). CSPTs/PEL NPs showed appropriate particle size and drug loading for drug delivery applications. On the contrary, CPT, HCPT, ACPT, and CPT-1a-CPT loaded NPs prepared similarly by co-precipitating with PEL





Figure 2. a) Preparation of CSPT/PEL NPs by nanoprecipitation, disassembly of the NPs in response to trigger-induced CSPT degradation, and drug release from the NPs. b) Release of HcPT and ACPT from CSPT(1a/HcPT)/PEL and CSPT(1a/ACPT)/PEL NPs, respectively, with continuous UV irradiation (+UV) or without UV (-UV) irradiation. c) Pulsatile release of HcPT and ACPT from CSPT(1a/HcPT)/PEL and CSPT(1a/ACPT)/PEL NPs in response to periodic UV irradiation for 1 min every 60 min.



Scheme 3. a) Synthesis of UV- and H₂O₂-responsive CSPTs. b) Proposed chain-shattering degradation and release of drugs from UV-responsive CSPTs upon UV irradiation.

in water afforded particles with very large particle size (over 1 μm), low drug loading and very low loading efficiency (under 10%; Table S1). CSPT(**1a**/HCPT)/PEL NPs showed excellent responsiveness to triggered-induced drug release. Without UV irradiation, the proportion of HCPT released from the NPs in phosphate buffered saline (PBS) solution was nearly negligible (Figure 2b). However, when the NPs were irradiated with UV light for 10 min, 59% of the HCPT was released (Figure 2b). Pulsatile release of HCPT from CSPT(**1a**/HCPT)/PEL NPs was also observed with periodic UV irradiation (Figure 2c). UV-responsive CSPT(**1a**/ACPT)/PEL NPs were similarly prepared, and they also showed burst release and pulsatile release of ACPT in response to UV irradiation (Figure 2b,c).

We evaluated the cytotoxicity of CSPTs/PEL NPs using microculture tetrazolium (MTT, MTT=3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Without UV treatment, CSPT(**1a**/HCPT)/PEL and CSPT(**1a**/ACPT)/PEL NPs showed low cytotoxicity in HeLa cells with IC_{50} values of 1230 nM and 1687 nM respectively (Figure 3a, b). Upon UV treatment, the IC_{50} values decreased substantially to 97 nM and 109 nM for CSPT(**1a**/HCPT)/PEL and CSPT(**1a**/ACPT)/PEL NPs, respectively, suggesting that the cytotoxicity of CSPTs/PEL NPs can be well controlled by external stimulations. Similarly, CSPT(**1b**/ACPT)/PEL NPs showed significantly higher cytotoxicity in the presence of H_2O_2 (IC_{50} = 113 nM) than the untreated CSPT(**1b**/ACPT)/PEL NPs (IC_{50} = 1436 nM) (Figure 3a,b). Degradation species from the control polymer (poly(**1a**/3), Scheme S7) without anticancer drugs showed negligible cytotoxicity to the same cell lines (Figure S20).

To further demonstrate the therapeutic efficacy of the CSPTs in vivo, we evaluated the triggered cell apoptosis in subcutaneous 4T1 tumors in BALB/c mice treated with the CSPTs/PEL NPs (Figure 3c,d; Figure S21). Tumors that were treated with CSPT(**1b**/ACPT)/PEL NPs intratumorally then treated with H_2O_2 showed 2.5-fold higher apoptosis index ($69.6 \pm 5.0\%$) compared to a control group without H_2O_2 treatment ($27.3 \pm 2.7\%$). To exclude the possibility that cell apoptosis were induced by H_2O_2 , mice were treated intratumorally with H_2O_2 (10 mM, 100 μL /tumor) alone; no significant cell apoptosis (with apoptosis index of $18.3 \pm 1.7\%$) was observed as compared to PBS (1 $\times$, 100 μL) negative control group (with apoptosis index of $15.2 \pm 4.8\%$; Figure 3c,d). Therefore,




Figure 3. a, b) Cytotoxicity of CSPTs/PEL NPs in HeLa cells. Triggering conditions: UV treatment (360 nm, 20 mW cm^{-2} , 10 min) for CSPT(**1a**/HCPT)/PEL NPs and CSPT(**1a**/ACPT)/PEL NPs; H_2O_2 treatment (1 mM) for CSPT(**1b**/ACPT)/PEL NPs. The half maximal inhibitory concentration (IC_{50}) values were determined by half-cell viability concentration from the MTT assay and summarized in the Table. c,d) BALB/c mice bearing subcutaneous 4T1 tumors received a single intratumoral injection of phosphate buffered saline (PBS), H_2O_2 , ACPT or CSPT(**1b**/ACPT)/PEL NPs (0.5 mg ACPT equiv./tumor) with or without H_2O_2 (10 mM, 100 μL /tumor). H_2O_2 was administered intratumorally 1 h after the injection of CSPT(**1b**/ACPT)/PEL NPs. The mice were sacrificed 48 h post injection. The 4T1 tumors were collected, sectioned, and stained with deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end (TUNEL) for apoptosis analysis. Representative images (c) and quantification by ImageJ (d) of TUNEL stains are shown. Scale bar: 50 μm . The apoptosis index was determined as the ratio of apoptotic cell number (TUNEL, green) to the total cell number (4',6-diamidino-2-phenylindole (DAPI), blue) (20 tissue sections were counted per tumor; $n = 4$; data are represented as average $\pm$ SEM and analyzed by One-way ANOVA (Fisher) ($*p < 0.05$; n.s. = not significant)).

the trigger-responsive CSPT(**1b**/ACPT)/PEL NPs markedly improved the antitumor efficacy by inducing higher apoptosis index in tumors with elevated level of reactive oxygen species, including H_2O_2 , which is one of the characteristics of tumor tissues.^[9]

The development of PTs for personalized medicine requires precise control over drug release; the payload ideally is retained in the delivery vehicle during circulation, tissue distribution, and cellular trafficking processes and then burst released when the delivery vehicle reaches the target cells or intracellular compartments. In this study, we designed 2,6-

bis(hydroxymethyl)anilines with UV- and redox-sensitive protecting groups and used these anilines as monomers for condensation with bifunctional drugs to create CSPTs, and as TRDs for controlling the complete drug release on a chain-shattering manner upon exposure of external triggers. Pulsatile drug release from the CSPTs was observed in response to periodically applied triggers. The trigger-responsive cytotoxicity and in vivo antitumor efficacy of CSPTs were demonstrated by applying external stimulations. This class of CSPTs showed unprecedented, active control over drug release and may become important building blocks for preparing the next-generation of controlled release devices and nanomedicines for in vitro and in vivo applications.

Received: January 20, 2013

Revised: February 19, 2013

Published online: May 6, 2013

Keywords: cancer therapy · controlled release · polymer–drug conjugate · polymers · trigger-responsive polymer

- [1] a) D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, *Nat. Nanotechnol.* **2007**, *2*, 751–760; b) D. W. Pack, A. S. Hoffman, S. Pun, P. S. Stayton, *Nat. Rev. Drug Discovery* **2005**, *4*, 581–593; c) V. Bagalkot, O. C. Farokhzad, R. Langer, S. Jon, *Angew. Chem.* **2006**, *118*, 8329–8332; *Angew. Chem. Int. Ed.* **2006**, *45*, 8149–8152; d) J. A. Johnson, Y. Y. Lu, A. O. Burts, Y. H. Lim, M. G. Finn, J. T. Koberstein, N. J. Turro, D. A. Tirrell, R. H. Grubbs, *J. Am. Chem. Soc.* **2011**, *133*, 559–566; e) M. Mammen, S. K. Choi, G. M. Whitesides, *Angew. Chem.* **1998**, *110*, 2908–2953; *Angew. Chem. Int. Ed.* **1998**, *37*, 2754–2794; f) W. A. Henne, D. D. Doorneweerd, A. R. Hilgenbrink, S. A. Kularatne, P. S. Low, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5350–5355; g) L. Y. Qiu, Y. H. Bae, *Pharm. Res.* **2006**, *23*, 1–30; h) M. E. Fox, F. C. Szoka, J. M. J. Frechet, *Acc. Chem. Res.* **2009**, *42*, 1141–1151; i) S. Venkataraman, J. L. Hedrick, Z. Y. Ong, C. Yang, P. L. R. Ee, P. T. Hammond, Y. Y. Yang, *Adv. Drug Delivery Rev.* **2011**, *63*, 1228–1246; j) H. R. Ihre, O. L. P. De Jesus, F. C. Szoka, J. M. J. Frechet, *Bioconjugate Chem.* **2002**, *13*, 443–452.
- [2] a) L. Erdmann, K. E. Uhrich, *Biomaterials* **2000**, *21*, 1941–1946; b) R. Duncan, *Nat. Rev. Cancer* **2006**, *6*, 688–701; c) C. Li, S. Wallace, *Adv. Drug Delivery Rev.* **2008**, *60*, 886–898; d) K. Ulbrich, V. Subr, *Adv. Drug Delivery Rev.* **2004**, *56*, 1023–1050; e) Z. Zhou, Y. Shen, J. Tang, M. Fan, E. A. Van Kirk, W. J. Murdoch, M. Radosz, *Adv. Funct. Mater.* **2009**, *19*, 3580–3589; f) R. Tong, D. A. Christian, L. Tang, H. Cabral, J. R. Baker, K. Kataoka, D. E. Discher, J. Cheng, *MRS Bull.* **2009**, *34*, 422–431.
- [3] a) J. A. MacKay, M. N. Chen, J. R. McDaniel, W. Liu, A. J. Simnick, A. Chilkoti, *Nat. Mater.* **2009**, *8*, 993–999; b) F. Canal, J. Sanchis, M. J. Vicent, *Curr. Opin. Biotechnol.* **2011**, *22*, 894–900; c) R. Duncan, *Curr. Opin. Biotechnol.* **2011**, *22*, 492–501; d) S. Aryal, C. M. J. Hu, L. Zhang, *ACS Nano* **2010**, *4*, 251–258; e) J. Su, F. Chen, V. L. Cryns, P. B. Messersmith, *J. Am. Chem. Soc.* **2011**, *133*, 11850–11853; f) Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, K. Kataoka, *Bioconjugate Chem.* **2005**, *16*, 122–130; g) H. Zhao, C. Lee, P. K. Sai, Y. H. Choe, M. Boro, A. Pendri, S. Y. Guan, R. B. Greenwald, *J. Org. Chem.* **2000**, *65*, 4601–4606.
- [4] a) T. Lammers, *Adv. Drug Delivery Rev.* **2010**, *62*, 203–230; b) P. Chytil, T. Etrych, C. Konak, M. Sirova, T. Mrkvan, J. Boucek, B. Rihova, K. Ulbrich, *J. Controlled Release* **2008**, *127*, 121–130; c) A. Nori, J. Kopecek, *Adv. Drug Delivery Rev.* **2005**, *57*, 609–636; d) M. C. Parrott, M. Finnis, J. C. Luft, A. Pandya, A. Gullapalli, M. E. Napier, J. M. Desimone, *J. Am. Chem. Soc.* **2012**, *134*, 7978–7982; e) T. Liu, X. Li, Y. Qian, X. Hu, S. Liu, *Biomaterials* **2012**, *33*, 2521–2531.
- [5] a) R. J. Christie, D. W. Grainger, *Adv. Drug Delivery Rev.* **2003**, *55*, 421–437; b) R. Duncan, M. J. Vicent, *Adv. Drug Delivery Rev.* **2010**, *62*, 272–282; c) K. Miller, R. Erez, E. Segal, D. Shabat, R. Satchi-Fainaro, *Angew. Chem.* **2009**, *121*, 2993–2998; *Angew. Chem. Int. Ed.* **2009**, *48*, 2949–2954; d) R. Satchi-Fainaro, H. Hailu, J. W. Davies, C. Summerford, R. Duncan, *Bioconjugate Chem.* **2003**, *14*, 797–804.
- [6] a) R. Erez, E. Segal, K. Miller, R. Satchi-Fainaro, D. Shabat, *Bioorg. Med. Chem.* **2009**, *17*, 4327–4335; b) M. Sirova, J. Strohalm, V. Subr, D. Plocova, P. Rossmann, T. Mrkvan, K. Ulbrich, B. Rihova, *Cancer Immunol. Immunother.* **2007**, *56*, 35–47; c) L. Kovar, T. Etrych, M. Kabesova, V. Subr, D. Vetricka, O. Hovorka, J. Strohalm, J. Sklenar, P. Chytil, K. Ulbrich, B. Rihova, *Tumor Biol.* **2010**, *31*, 233–242; d) V. R. Caiola, M. Zamai, A. Fiorino, E. Frigerio, C. Pellizzoni, R. d'Argy, A. Ghiglieri, M. G. Castelli, M. Farao, E. Pesenti, M. Gigli, F. Angelucci, A. Suarato, *J. Controlled Release* **2000**, *65*, 105–119.
- [7] a) R. Tong, J. Cheng, *Angew. Chem.* **2008**, *120*, 4908–4912; *Angew. Chem. Int. Ed.* **2008**, *47*, 4830–4834; b) R. Tong, J. Cheng, *J. Am. Chem. Soc.* **2009**, *131*, 4744–4754; c) R. Tong, L. D. Yala, T. M. Fan, J. Cheng, *Biomaterials* **2010**, *31*, 3043–3053; d) R. Tong, J. Cheng, *Bioconjugate Chem.* **2010**, *21*, 111–121; e) R. Tong, J. Cheng, *Macromolecules* **2012**, *45*, 2225–2232.
- [8] Y. Zhang, L. Ma, X. Deng, J. Cheng, *Polym. Chem.* **2013**, *4*, 224–228.
- [9] a) W. Bechtel, G. Bauer, *Anticancer Res.* **2009**, *29*, 4559–4570; b) G. Mantovani, A. Maccio, C. Madeddu, L. Mura, E. Massa, G. Gramignano, M. R. Lusso, V. Murgia, P. Camboni, L. Ferreli, *J. Cell. Mol. Med.* **2002**, *6*, 570–582; c) H. Sies, *Angew. Chem.* **1986**, *98*, 1061–1075; *Angew. Chem. Int. Ed. Engl.* **1986**, *25*, 1058–1071; d) D. Yoo, H. Jeong, C. Preihs, J. S. Choi, T. H. Shin, J. L. Sessler, J. Cheon, *Angew. Chem.* **2012**, *124*, 12650–12653; *Angew. Chem. Int. Ed.* **2012**, *51*, 12482–12485.